GSK: Result Summaries: Compounds

Home > Result Summaries: Compounds > eltrombopag

Result Summaries: eltrombopag

Result Summaries for eltrombopag
GSK Study ID	Phase	Title
102860	Phase 1	A Two-Part, Randomized, Placebo-Controlled Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Single, Oral Doses of the Thrombopoietin Receptor Agonist, Eltrombopag; and the Effect of Eltrombopag on Cardiac Repolarization as Compared to Placebo and Single Oral Doses of Moxifloxacin in H (0 citation(s))
102861	Phase 1	An Open-Label Mass Balance Study to Investigate the Metabolic Disposition of a Single Oral Dose of 14C SB-497115-GR in Healthy Male Subjects. (0 citation(s))
102863	Phase 1	An open-label, randomized, five-period, period-balanced, crossover study to assess the effect of food and antacid on the pharmacokinetics of a single dose of SB-497115-GR (eltrombopag) in healthy volunteers (0 citation(s))
104603	Phase 1	: Phase I Study of SB-497115-GR – Single Oral Dose Study in Healthy Japanese Male Subjects – (0 citation(s))
104631	Phase 1	An open-label, randomized, five-period, period-balanced, crossover study to assess the effect of food and antacid on the pharmacokinetics of a single dose of SB-497115-GR (eltrombopag) in healthy volunteers (0 citation(s))
105120	Phase 1	An Open-label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rosuvastatin when Co-administered with Eltrombopag (SB-497115-GR) in Healthy Adult Subjects (0 citation(s))
105122	Phase 1	Phase I Bioequivalence Study for SB-497115-GR Phase II and Phase III Tablets (0 citation(s))
105580	Phase 1	Phase I Study of SB-497115-GR - Single and Multiple Oral Dose Study in Healthy Japanese Male Subjects - <Clinical Pharmacology Study> (0 citation(s))
108109	Phase 3	Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) -A Multicenter Study in Subjects with Chronic ITP Receiving a Double-Blind, Placebo-Controlled, Short-Term Treatment Followed by an Open-Label, Uncontrolled, Long-Term Treatment- <Phase II/III Study> (0 citation(s))
111716	phase 1	A Phase I, Open-label, Single Sequence, Crossover Study Evaluating the Safety and the Pharmacokinetics of Lopinavir/Ritonavir and Eltrombopag Given Alone and when Co-administered in Healthy Adult Subjects. (0 citation(s))
111913	Phase 2	TPL111913, a Multi-centre, Open Label, Dose Ranging Phase II Study to Assess Efficacy, Safety and Pharmacokinetics of Eltrombopag in Japanese Thrombocytopenic Subjects with Chronic Liver Disease (0 citation(s))
497115/003	Phase 2	A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist(SB497115-GR) Administered at 50, 75, and 100 mg to Cancer Patients Receiving Multiple Cycles of Chemotherapy (0 citation(s))
TPL102357	Phase 2	A Double-Blind, Randomized, Placebo-Controlled, Multi-Centre, Dose-Ranging, Parallel Group, Phase II Study to Assess Efficacy, Safety/Tolerability, and Pharmacokinetics of a Thrombopoietin Receptor Agonist, SB-497115-GR, when Administered as 30, 50, and 75 mg Once Daily for 12 weeks in Subjects with (1 citation(s))
TPL104054	Phase 3	Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures (0 citation(s))
TRA100773	Phase 2	See Detailed Description (1 citation(s))
TRA100773_B	Phase 3	A double-blind, randomized, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of SB-497115-GR, a thrombopoietin receptor agonist, administered at 30, 50 and 75 mg as oral tablets once-daily for 6 weeks to adult male and female sub (2 citation(s))
TRA102537	phase 3	A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administered for 6 months as oral tablets once daily in adult subjects with previously treated chronic ITP. (0 citation(s))
TRA103452	phase 1	An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral dose of 50mg Eltrombopag in Healthy Subjects and in Volunteers with Mild, Moderate or Severe Hepatic Impairment (0 citation(s))
TRA104412	Phase 1	An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral Dose of 50 mg [SB-497115] in Healthy Subjects and in Subjects with Mild, Moderate, or Severe Renal Impairment (0 citation(s))
TRA106914	Phase 1	A phase I, double-blind, placebo and observer-blind positive controlled, randomized, parallel group study in healthy subjects to investigate the photoirritant potential of eltrombopag (0 citation(s))
TRA108057	Phase 2	An Open-label repeat dosing study of eltrombopag olamine (SB-497115-GR) in adult subjects, with chronic idiopathic thrombocytopenic purpura (ITP) (0 citation(s))

Result Summaries: eltrombopag

Filter list by: